Philippe BARTH

OVER THE PAST TEN YEARS, HTI HAS CONSOLIDATED ITS POSITION AS A EUROPEAN LEADER IN SEARCH AND SELECTION FOR THE HEALTHCARE TECHNOLOGY INDUSTRY AND SERVICE SECTORS – ITS SPECIALITY AND UNIQUE FOCUS.

HTI team has many years of experience in all sectors of the Healthcare and Technology industries. Our backgrounds are in International General, Technical Scientific, Sales & Marketing and Human Resources management. Therefore we understand the technology, the market and the needs of our clients and we work with them as part of their team.

HTI cover the full spectrum of Life-Sciences and Technology in the following areas:

Pharmaceutical
Medical devices
Medical equipment
Diagnostics
Biotechnology
Vaccines
Blood products
Veterinary
Biomaterials
Healthcare delivery
New technologies / Internet based services
CRO and similar service companies
Healthcare Trade Associations
Life Science venture Capital

HTI has a broad experience in filling positions with European responsibilities, as well as at a country level.
Our national experience is Europe-wide.
We are competent and skilled in all therapeutic areas.

http://www.hti-consulting.com

Philippe BARTH (58) MD, MBA, is a seasoned Life Science professional. His unique cursus spans from Clinical Research to global R&D management, Venture Capital, Start-up CEO and Executive Consulting.

• PHARMA (1981 – 2001)
Initially operating as an Int'l Clinical Development specialist (BAYER Pharma, WELLCOME (now GSK) and GUERBET), he joined in 1989 MERCK-LIPHA (now MERCK-SERONO) as R&D board member and Director Int’l Clinical Development (team: 40p in Europe). In 1996 he was promoted Director Strategic Planning & Alliances supervising the Metabolism R&D team (450p - 140 projects - Budget 130M€).

• VENTURE CAPITAL (2001-2003)
As Senior PARTNER with SIPAREX Ventures, he started from scratch the Life Sciences & Biotech investments creating a portfolio of 9 companies (14M€), in which he served as "hands on" Board Member.

• CONSULTING: Strategy – Finance – Executive Search
Since 2003, he operates as an independent Sr BIOTECH CONSULTANT and has advised until now more than 60 Venture Capital, life sciences and high-tech companies and project holders in the fields of due diligences, strategy, capital rising, M&A, leasing.
Early 2009, to complete his consulting offer, he joined the consultants team of HTI, a well established European Executive Search firm uniquely focusing on Life Science industries.

• START-UP CEO (2006-2008)
As President & CEO of MELLITECH, a red-biotech start-up focusing on the R&D of exclusive treatments and diagnostics for T2-Diabetes, he successfully started the company from the incubator to seed capital rising (1/2M€), negotiating in & out licences, commercial deals and R&D partnerships and introduced the company to his large VC and big-pharma network.

• EDUCATION
Dr BARTH received a Medical Degree from the University of Paris (1981) and post-doc degrees in Toxicology, Clinical Pharmacology and Sport Medicine.
He holds a Senior Executive MBA (EM Lyon CPA 1995/L).

Specialties:
General Management of biotech companies, Fund raising, licensing, M&A, Business Development, Executive Search. Active professional networks in Venture Capital and Pharmaceutical Companies

Mobile +33 (0)622 258 778
Email philippe_barth@hotmail.com

Octobre 2006 – Juillet 2008
CEO - Président du Directoire – Actionnaire fondateur

Lancement d’une Start-up Biotech « rouge » spécialisée dans le DIABETE
(Thérapeutique + Imagerie + Diagnostic)
Main Achievements :
o Analyse stratégique et établissement du Business Plan
o Management de la société et relations avec les actionnaires
o Négociation Brevet « maître » auprès d’établissements académiques (CEA, UJF)
o Négociation partenariat industriel
o Levée de fonds auprès de 14 Business Angels (Loi TEPA / ISF)
o Négociation accord commercial
o Négociation Licence produit (out licensing) à industriel international
o Négociation partenariat de discovery avec Big Pharma